$0.06 EPS Expected for PDL BioPharma, Inc. (PDLI)

April 17, 2018 - By Dolores Ford

PDL BioPharma, Inc. (NASDAQ:PDLI) LogoInvestors sentiment decreased to 1.13 in Q4 2017. Its down 0.37, from 1.5 in 2017Q3. It dived, as 18 investors sold PDL BioPharma, Inc. shares while 52 reduced holdings. 26 funds opened positions while 53 raised stakes. 134.59 million shares or 2.55% more from 131.24 million shares in 2017Q3 were reported.
Amundi Pioneer Asset Management Inc reported 0% stake. Brandes Investment Prtnrs Limited Partnership holds 0.06% or 1.10M shares. Huntington National Bank & Trust invested in 1,000 shares. Gsa Cap Prtnrs Limited Liability Partnership reported 357,181 shares or 0.06% of all its holdings. Ubs Asset Americas invested 0% of its portfolio in PDL BioPharma, Inc. (NASDAQ:PDLI). Regions invested in 0% or 425 shares. Aqr Mgmt holds 0.02% or 5.36 million shares in its portfolio. Ameritas Investment Prtn Inc holds 0% or 12,664 shares. Metropolitan Life owns 0% invested in PDL BioPharma, Inc. (NASDAQ:PDLI) for 41,688 shares. 55,000 are held by State Of New Jersey Common Pension Fund D. Alps Advsrs accumulated 317,145 shares or 0.01% of the stock. Moreover, Goldman Sachs Inc has 0% invested in PDL BioPharma, Inc. (NASDAQ:PDLI) for 1.36M shares. Tower Capital Ltd Limited Liability Company (Trc) holds 0% or 4,727 shares in its portfolio. Citigroup holds 0% in PDL BioPharma, Inc. (NASDAQ:PDLI) or 299,420 shares. Cornerstone Cap Mgmt Limited Liability Co accumulated 0% or 125,096 shares.

Analysts expect PDL BioPharma, Inc. (NASDAQ:PDLI) to report $0.06 EPS on May, 2.They anticipate $0.02 EPS change or 25.00 % from last quarter’s $0.08 EPS. PDLI’s profit would be $9.23M giving it 12.52 P/E if the $0.06 EPS is correct. After having $0.17 EPS previously, PDL BioPharma, Inc.’s analysts see -64.71 % EPS growth. The stock increased 0.17% or $0.005 during the last trading session, reaching $3.005. About 309,624 shares traded. PDL BioPharma, Inc. (NASDAQ:PDLI) has risen 39.51% since April 17, 2017 and is uptrending. It has outperformed by 27.96% the S&P500.

PDL BioPharma, Inc. (NASDAQ:PDLI) Ratings Coverage

Among 2 analysts covering PDL BioPharma (NASDAQ:PDLI), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. PDL BioPharma had 2 analyst reports since October 26, 2017 according to SRatingsIntel. Piper Jaffray maintained the stock with “Buy” rating in Friday, November 3 report. The rating was maintained by Cowen & Co with “Hold” on Thursday, October 26.

PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company has market cap of $462.21 million. The firm operates through two divisions, Income Generating Assets and Product Sales. It has a 4.23 P/E ratio. The Income Generating Assets segment consists of royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri; and notes and other long-term receivables, royalty rights, hybrid notes/royalties receivable, and equity investments in healthcare companies.

PDL BioPharma, Inc. (NASDAQ:PDLI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: